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Background: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitors have been recently developed to
inhibit NS5A activities and have been approved for the treatment of HCV infection. However the drawback of these
direct acting antivirals (DAAs) is the emergence of resistance mutations. The prevalence of such mutations conferring
resistance to HCV-NS5A inhibitors before treatment has not been investigated so far in the Tunisian population. The
aim of this study was to detect HCV variants resistant to HCV-NS5A inhibitors in hepatitis C patients infected with HCV
genotype 1 before any treatment with NS5A inhibitors.
Methods: Amplification and direct sequencing of the HCV NS5A region was carried out on 112 samples from 149
untreated patients.
Results: In genotype 1a strains, amino acid substitutions conferring resistance to NS5A inhibitors (M28V) were detected
in 1/7 (14.2 %) HCV NS5A sequences analyzed. In genotype 1b, resistance mutations in the NS5A region (R30Q; L31M;
P58S and Y93H) were observed in 17/105 (16.2 %) HCV NS5A sequences analyzed. R30Q and Y93H (n = 6; 5.7 %)
predominated over P58S (n = 4; 3.8 %) and L31M (n = 3; 2.8 %).
Conclusions: Mutations conferring resistance to HCV NS5A inhibitors are frequent in treatment-naïve Tunisian
patients infected with HCV genotype 1b. Their influence in the context of DAA therapies has not been fully investigated
and should be taken into consideration.
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Hepatitis C virus (HCV) infection is the major cause of
chronic liver disease which can progress to cirrhosis and
hepatocellular carcinoma over the course of 20–30 years
[1]. Globally HCV has infected 180 million people, approxi-
mately 3 % of the world’s population [2]. It is an enveloped
positive-strand RNA virus and is the only member of the
Hepacivirus genus of the Flaviviridae family [3]. Based on* Correspondence: jamel.larous@gmail.com
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creativecommons.org/publicdomain/zero/1.0/phylogenetic analysis, HCV has been classified into six dif-
ferent genotypes and diverse subtypes [4].
Tunisia is one of the countries with low endemicity
for HCV. The prevalence of HCV infection is less than
1 % [5, 6] with an average prevalence of 80 % of subtype
1b [7, 8]. The current standard therapy in Tunisia con-
sists of pegylated alpha interferon (PEG-IFNα) combined
with ribavirin (RBV), a nucleoside analogue, for 24–48
weeks [9]. This treatment is associated with a high long-
term response rate in patients infected with HCV genotype
2 and 3, whereas a sustained virologic response (SVR) can
be achieved only in 50 % of patients infected with HCV
genotype 1 [10–12].
Recently, direct-acting antivirals (DAAs) that target
specific viral proteins of the HCV life cycle, have been
developed and some of them have already been approvedccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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combination with PEG-IFNα/RBV as well as in IFN-free
regimens [13]. These molecules include a range of non-
structural (NS) 3/NS4A protease, NS5B polymerase and
NS5A inhibitors [14].
NS5A inhibitors target the domain I of NS5A protein
and have been shown to block phosphorylation of NS5A,
which is essential for viral RNA replication and inhibits
the assembly and release of viral particles [15, 16]. These
inhibitors have been tested in clinical trials. Data for first-
generation NS5A inhibitors such as daclatasvir (DCV),
ledipasvir (LDV) and ombitasvir (OBV) are available. The
effectiveness of DCV has been studied in combination
with PEG-IFNα/RBV among naïve patients. For a treat-
ment lasting of 24 or 48 weeks, SVR rates were 59 and
58 % in patients with subtype 1a, 78 and 87 % in patients
with subtype 1b, and 67 and 100 % in patients with HCV
genotype 4, respectively [15]. In naïve patients, the com-
bination of sofosbuvir (SOF)/LDV, administered for
12 weeks with or without RBV, has been associated with
SVR rates of 95 % [17, 18]. Similar response rates were
obtained with treatment durations of only 8 weeks in pa-
tients with a fibrosis score of F0-F1 [18]. In patients failing
a first-line therapy with the association PEG-IFNα/RBV/
first-generation protease inhibitors, SVR rates with SOF/
LDV were 95 and 99 % after 12 and 24 weeks of treatment
respectively [17]. OBV was evaluated in vivo in a 3-day
monotherapy study in 12 HCV genotype 1-infected
patients at 5, 25, 50 and 200 mg dosed once daily and
showed significant efficiency [19].
The rapid replication rate of HCV and the low fidelity
of its polymerase result in a sequence variation in the
HCV population, leading to a quasi-species and the poten-
tial selection of drug-resistant mutations [14]. The efficacy
of DAA is limited by the presence of these mutations
resulting in amino acid substitutions within the targeted
proteins which affect viral sensitivity to these compounds
[14]. Monotherapy studies with NS5A inhibitors have re-
vealed the rapid emergence of resistance mutations to
these drugs [20]. In vitro or in vivo, five major positions of
mutations in the NS5A HCV protein (28; 30; 31; 58 and
93) have been reported to be associated with different
levels of resistance to NS5A inhibitors [14]. It has been
demonstrated that HCV NS5A inhibitors should be used
in combination regimens potent enough to prevent the
emergence of resistance mutations [21].
Variants conferring resistance to NS5A inhibitors exist
naturally within HCV quasispecies populations in the
absence of any previous exposure to these drugs [16,
22–24] while they are frequently selected at failure with
treatment including HCV NS5A inhibitors [21].
HCV NS5A inhibitors are not yet available in Tunisia,
but it is very important to determine the natural preva-
lence of such substitutions conferring resistance to NS5Ainhibitors before their introduction in the country for
more extensive treatment of HCV infection.
The aim of this study was to investigate the natural
prevalence of mutations conferring resistance to NS5A
inhibitors in clinical strains from treatment-naïve Tunisian
patients infected with HCV genotype 1.Results
Baseline characteristics of the patients
All patients were infected with HCV genotype 1 (1b: 142;
1a:7), all of them were naïve of anti-HCV treatment and
none was co-infected with hepatitis B virus (HBV) or hu-
man immunodeficiency virus (HIV). Their median age was
56 years. Forty-five patients (30 %) out of 149 were male
and 104 patients (70 %) were female. The median HCV
load was 1,955,625 IU/ml [range 9140-16,800,000 IU/ml].
49 % of patients had liver cirrhosis.Prevalence of NS5A inhibitor resistance mutations
The NS5A gene was successfully sequenced in 112 out
of 149 (75.1 %) samples that were amplified by nested
PCR. Among the 112 NS5A sequences obtained, 7 se-
quences (6.2 %) were HCV genotype 1a and 105 (93.8 %)
HCV genotype 1b.
Sequencing and alignments of the 112 NS5A sequences
allowed the identification of amino acid substitutions im-
plicated in resistance to HCV NS5A inhibitors (Table 1).
Amino acid substitutions conferring resistance to
HCV NS5A inhibitors were detected in both subtypes 1a
and 1b strains.
In subtype 1a strains, amino acid substitutions confer-
ring resistance to HCV NS5A inhibitors were observed
in 1 sequence out of 7 (14.2 %). This sequence showed
the M28V substitution associated with very low-level
resistance to DCV and displayed 58-fold resistance to
OBV.
In genotype 1b strains, amino acid substitutions asso-
ciated with resistance to HCV NS5A inhibitors were
observed in 17/105 (16.2 %) sequences analyzed. Three
sequences (3/105; 2.8 %) exhibited the substitution
L31M and six sequences (6/105; 5.7 %) showed the
Y93H variant. These mutations are considered as pri-
mary resistance mutations. The L31M substitution is
known to confer 3-fold resistance to DCV and 2.09-fold
resistance to LDV. The Y93H mutation is known to
confer 24-fold resistance to DCV, 77-fold resistance to
OBV and very high-level resistance to LDV yielding
1319-fold resistance. Six sequences (6/105; 5.7 %) ex-
hibited the R30Q substitution and P58S was present in
four sequences (4/105; 3.8 %). These two substitutions
are known as secondary resistance mutations that in-
crease the resistance of primary mutations but do not
confer resistance by themselves.
Table 1 Amino acid substitutions in NS5A region of treatment-naïve patients infected with HCV genotypes 1a (n = 7) and 1b (n = 105)
NS5A residues Resistance mutations Prevalence of observed resistance mutations (%) DAAs
Genotypes Genotypes Genotypes
1a 1b 1a 1b 1a 1b
L23 F Daclatasvir
M28 L28 T/V M/V V (1/7; 14.2 %) Daclatasvir Ombitasvir
Q30 R30 H/E/R/K Q Q (6/105; 5.7 %) Daclatasvir Ombitasvir
L31 L31 M/V F/M/V M (3/105; 2.8 %) Daclatasvir Ledipasvir Ombitasvir
P32 P32 L L Daclatasvir
P58 S S (4/105; 3.8 %) Daclatasvir
Y93 Y93 C/H/N C/H/N H (6/105; 5.7 %) Daclatasvir Ledipasvir Ombitasvir
Data interpreted according to Krishnan et al. [19] Paolucci et al. [24] and Fridell et al. [27]
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contained the P32L mutation, which is known to be a
primary resistant variant associated with high-level re-
sistance to HCV NS5A inhibitors.
Combinations of viral variants in the NS5A region
were rare. No combinations of viral variants were observed
in genotype 1a. Among the 105 NS5A 1b sequences ana-
lyzed, only two sequences (2/105; 1.9 %) showed combina-
tions of two resistant variants R30Q +Y93H. When present
on the same genome, this combination is known to confer
284-fold resistance to OBV.
Discussion
In this study, the first in the Tunisian population, 149
treatment-naïve patients infected with HCV genotype 1
were evaluated to determine the natural prevalence of
HCV variants resistant to NS5A inhibitors. The sequencing
technology used was the Sanger method which is known to
allow detection of dominant variant populations above
20 %. We cannot eliminate minor variant populations that
might have been detected by ultra-deep pyro-sequencing,
whose threshold for detecting minor variants is estimated
to be fairly lower than the Sanger threshold.
Baseline identification of pre-existing mutations resistant
to anti-HCV inhibitors in treatment-naïve patients is essen-
tial for defining new DAAs therapies [24]. Some studies
have reported that all amino acid substitutions associated
with resistance to HCV NS5A inhibitors are located in the
N-terminal region of NS5A [25, 26]. Of note, some studies
have shown that the majority of resistance mutations
observed in vivo are at positions M28, Q30, L31 and
Y93 for HCV genotype 1a and at positions L31 and Y93
for genotype 1b [27, 28].
In this work some resistance mutations conferring re-
sistance to HCV NS5A inhibitors such as DCV, LDV
and OBV were observed. One out of 7 (14.2 %) patients
with subtype 1a and 17 out of 105 (16.2 %) with subtype
1b showed amino acid substitutions within the NS5A
inhibitor resistance sites. In this study, the number ofpatients infected with HCV genotype 1b was very large
compared to the number of patients infected with HCV
genotype 1a, which is due to the high 80 % prevalence
of genotype 1b in Tunisia [6–8]. In view of the low
number of 1a isolates studied, it is not possible to make
a definitive comparison of the resistance mutation to
NS5A inhibitors between both subtypes.
Some studies have described the natural prevalence of
substitutions conferring resistance to HCV inhibitors in
patients naïve to treatment with NS5A inhibitors. In
Italy, Paolucci et al. reported a frequency of 12.5 % and
53.3 % of substitutions involved in resistance to HCV
NS5A inhibitors in DAA treatment-naïve patients in-
fected with genotype 1a and 1b, respectively [24]. Suzuki
et al. reported 11.2 % of mutations L31M/V and Y93H
conferring resistance to HCV NS5A inhibitors in treat-
ment-naïve patients infected with HCV genotype 1b in
Japan [23]. In the present study we considered all muta-
tions conferring resistance to HCV NS5A inhibitors for
genotype 1b and our results are close to those provided
by Suzuki et al.
In subtype 1b strains, the primary resistance mutations
L31M conferring low-level resistance to DCV [27] and
Y93H conferring high-level resistance to DCV [27] and
OBV [19] and very high-level resistance to LDV [24] were
observed in three (2.8 %) and six sequences (5.7 %),
respectively. A previous study demonstrated that the
prevalence of these two key mutations associated with
resistance to NS5A inhibitors ranges from 6 to 12 %
among genotype 1b sequences [29]. The prevalence of
these mutations may reduce the barrier of resistance
and influence virologic response [29]. Bartels et al.
found a prevalence of 6.2 % and 3.7 % of the resistant
variants L31M and Y93H, respectively in patients infected
with subtype 1b [30]. These results are close to those ob-
served in the present study. Substitutions associated with
resistance to NS5A inhibitors have been associated with
low rates of virologic response in some DCV-based regi-
mens [29]. However, Suzuki et al. demonstrated in a phase
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mutations to NS5A inhibitors were cured of their chronic
HCV infection [31].
Moreover, other substitutions like R30Q (5.7 %) and
P58S (3.8 %) were found. These variants are known as
secondary resistance mutations that increase the resist-
ance of primary mutations but do not confer resistance
by themselves [25]. None of the 112 NS5A sequences
analyzed for either subtype showed any substitution at
position 32, which is known to confer high-level resist-
ance to DCV for subtype 1a [25] and a moderate level of
resistance for subtype 1b [25]. These results are similar
to those in Bartels’ study [30].
In subtype 1a, a primary resistance mutation in the
NS5A region M28V conferring low-level resistance to
DCV [25] and high-level resistance to OBV [19] was
observed in one sequence (14.2 %). One study has dem-
onstrated that DCV is characterized by a low genetic
barrier of resistance, notably for genotype 1a in which
the resistance to the drug can be acquired through a
single mutation [29].
In conclusion, the present study in treatment-naïve
Tunisian patients infected with HCV genotype 1b
demonstrates a significant proportion of substitutions
conferring resistance to HCV NS5A. Their influence
in the context of DAAs therapies has not yet been fully in-
vestigated and should be taken into consideration. Further
studies are needed to determine the impact of the NS5A
baseline resistance mutations on the treatment outcome
in clinical trials investigating combination therapies of
NS5A inhibitors with other classes of DAAs, although it
can be predicted that combination therapies would raise
the resistance barrier and reduce the importance of




The current study included 149 Tunisian patients infected
with HCV genotype 1 who were referred to the gastro-
enterology department in three Tunisian University
Hospitals between 2009 and 2011: Habib Bougatfa
University Hospital (Bizerte), La Rabta University Hos-
pital (Tunis) and Mohamed Tahar Maamouri University
Hospital (Nabeul). Plasma samples were collected from
each patient after obtaining written informed consent.
NS5A amplification
Total RNA was extracted from 140 μl of plasma using
the QIAamp viral RNA method (Qiagen, Courtaboeuf,
France) according to the manufacturer’s recommendations.
After reverse transcription (RT) using the SuperScript® III
One-Step RT-PCR system with Platinum® Taq High Fidelity
DNA Polymerase (Invitrogen, Cergy-Pontoise, France), anested-polymerase chain reaction (nested-PCR) was per-
formed with AmpliTaq Gold DNA Polymerase (Applied
Biosystem, Courtaboeuf, France).
HCV RNA was amplified as previously described using
primers 1a-NS5A-F0 (5’-GACATCTGGGACTGGATAT
GYGA -3’; nt 6276–6298) and 1a-NS5A-R0 (5’- GTCCAG
GWRTARGACATYGAGCA-3’; nt 7599–7621) for subtype
1a and 1b-NS5A-F0 (5’- GAYGTTTGGGAYTGGATATG
CAC-3’; nt 6276–6298) and 1b-NS5A-R0 (5’- GTCCAYG
WRTARGACATYGAGCA -3’; nt 7599–7621) for subtype
1b. The PCR product obtained was 1345 bp in size [24].
Briefly, the PCR products in the first PCR round were ob-
tained by using the following conditions: 30 min at 50 °C
for the RT followed by denaturation at 94 °C for 10 min
and then 40 cycles of amplification. Each cycle consisted of
denaturation at 94 °C for 15 s, annealing at 60 °C for 30 s,
and extension at 68 °C for 2 min. These steps were followed
by an extension step at 68 °C for 10 min.
For the nested PCR, two overlapping fragments of
DNA were amplified. For subtype 1a, the first fragment
was amplified as previously described [24] using the
primers 1a-NS5A-F1 (5’- GATATGYGAGGTGYTGAGC
GA-3’; 6290–6310) and 1a-NS5A-SeqR (5’- AAGGAGTCC
ARRATCACCAC -3’; nt 7089–7108) and the second
fragment was amplified using the primers 1a-NS5A-
SeqF (5’- ARCTGTCYGCWCCATCTCTCAAGG-3’; nt
6955–6978) and 1a-NS5A-R0 the same primer used in
the first PCR round.
For subtype 1b, the first fragment was amplified using
the primers 1b-NS5A-F1 (5’-GATATGYACGGTGYTGAY
TGA-3’; nt 6290–6310) and 1b-NS5A-SeqR (5’- AARGAG
TCCARRATYACYAC -3’; nt 7089–7108) and the second
fragment was amplified using the primers 1b-NS5A-SeqF
(5’- ARCTGTCYGCWCCATCTCTCAAGG -3’; nt 6955–
6978) and 1b-NS5A-R0 as previously described [24]. For
both subtypes, the PCR products obtained were 818 bp and
666 bp in size for the first and second amplified fragments,
respectively.
Two microliters from the first PCR reaction were used
in the nested PCR. The amplification conditions were
the same for both subtypes: initiation of denaturation at
95 °C for 10 min followed by 40 cycles consisting of de-
naturation at 95 °C for 30 s, primer annealing at 56 °C
for 30 s, and primer extension at 72 °C for 2 min,
followed by a final extension of 10 min at 72 °C. The
PCR amplification products were visualized on 1.5 %
agarose gel stained with ethidium bromide under UV
transilluminator after electrophoresis.
NS5A direct sequencing and sequence analysis
The nested PCR products were purified using the Micro-
spin™ S-400 HR Columns, GE Healthcare, Buckinghamshire,
UK) according to the manufacturer’s instructions. DNA
sequencing was performed using the Big Dye® Terminator
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cer (Appied Biosystem, Courtaboeuf, France). The same
primers used in the two semi-nested PCR for the amplifi-
cation of the NS5A region for both subtypes 1a and 1b
were used for sequencing in this region.
Nucleotide sequences were aligned with reference
sequences of different subtypes with SeqScape v 2.7
(Applied Biosystem, Courtaboeuf, France) and analyzed
for the presence of previously identified mutations confer-
ring resistance to NS5A inhibitors. GeneBank accession
numbers for NS5A reference sequences are AF009606 for
subtype 1a and AY045702 for genotype 1b. The threshold
of nucleotide mixture detection during sequencing of sam-
ples is estimated to be around 20 %.
Mutations conferring resistance to HCV NS5A inhibitors
NS5A sequences were screened for amino acid substitu-
tions conferring resistance to NS5A inhibitors. For geno-
type 1b, sequences were screened for variants L31F/M/
V, P32L and Y93C/H/N, which act as primary resistance
mutations and L23F, R30Q and P58S, which act as second-
ary resistance substitutions, thus enhancing the resistance
of primary mutations but not conferring resistance by
themselves. For subtype 1a, sequences were screened
for substitutions M28T/V, Q30H/E/R/K, L31M/V, P32L
and Y93C/H/N, which act as primary resistance muta-
tions [19, 24, 25, 27].
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